Novoeight® is designed for portability—to fit into patients' daily lives.

Novoeight® offers features that allow patients to treat on-the-go, at every stage of life. Novoeight® supports your patients' need for storage flexibility.

Your patients and caregivers say they prefer room-temperature stable treatment.

8 out of 10 human silhouettes. 80%

80% of patients and caregivers surveyed prefer a FVIII treatment that can be stored at room temperature for up to 12 hours.1,a


80% of patients and caregivers surveyed prefer a FVIII treatment that can be stored at room temperature for up to 12 hours.1,a

Novoeight® offers storage flexibility for a busy lifestyle.

The highest storage temperature for the longest duration2,b

Before reconstitution

Longest room temperature storage time after reconstitution2,b

After reconstitution


Please see Prescribing Information for complete storage instructions.

aFrom a web-based survey of 145 patients and caregivers.
bCompared with other recombinant rFVIII products.3-11

Prefilled syringe means quick reconstitution.

  • Each box comes with a prefilled diluent syringe
  • 4 mL of diluent—works with any dose strength2 
  • With MixPro®, preparing a dose is as quick as attach, twist, mix2

See full reconstitution instructions.

Attach
Attach
twist
twist
and mix
and mix
Attach, twist, and mix

Available in multiple dose strengths.

  • Help more patients infuse with fewer vials2
  • Vials have color-coded caps for easy recognition of different doses2
  • Peel-off labels make tracking treatments easy
6 different colored Novoeight® vials
6 different colored Novoeight® vials

Compact packaging.

  • Easy to store
  • Fits in a briefcase, backpack, or carry-on bag
  • Supports busy lifestyles
 Novoeight® zippered travel case
 Novoeight® zippered travel case

The Novoeight® Travel Kit is designed to go where they go.

 

  • The durable, lightweight case makes traveling easy
  • Patients can choose from 9 design options or upload their own image

Explore treatment options.

Our rFVIII Comparison Guide highlights how the portability of Novoeight® fits into your patients’ lives.

Dosing guidelines for Novoeight®.

Dosing guidelines for Novoeight®.

Novoeight® prefilled syringe

Refer to our dosing tables for recommendations.


Supporting your patients.

Supporting your patients

 Novoeight® brochure

Novo Nordisk offers insurance coordination and other support.


Have a question? We’re here to help.

Have a question? We’re here to help.

Five standing human silhouettes

Talk to a Novo Nordisk Representative about the educational resources available to you.

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.

References

  1. DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014;20(4):e296-e303.
  2. Novoeight [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2016.
  3. Kogenate® [package insert]. Tarrytown, NY: Bayer HealthCare LLC; 2014.
  4. Advate® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2015.
  5. Eloctate™ [package insert]. Cambridge, MA: Biogen Idec Inc.; 2016.
  6. Adynovate® [package insert]. Westlake Village, CA: Baxalta US Inc.; 2016.
  7. Recombinate® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2010.
  8. Xyntha® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2014.
  9. Afstyla® [package insert]. Kankakee, IL: CSL Behring LLC; 2016.
  10. Nuwiq® [package insert]. Hoboken, NJ: Octapharma USA, Inc.; 2015.
  11. ReFacto® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2007.